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Book of the month The Psychopharmacologists
David Healy is one of the most remarkable figures in contemporary psychiatry. He combines the skills of an historian with a training in laboratory psychopharmacology, a research interest in psychopathology, and an encyclopaedic knowledge of the psvchotherapies. Throughout the past decade he has published books and papers on subjects as diverse as phenomenology, nosology, hysteria, and psychopharmacology, including a marvellous user's handbook of psychiatric drugs. His latest book, The Psychopharmacologists III, is about the process of therapeutic innovation in clinical science and the forces that impinge on that process. An introduction and background material are followed by indepth interviews with twenty-seven individuals who played key parts in the discovery and deployment of drugs that have proved useful in psychiatry. The Psychopharmacologists II completes a trilogy and is best considered alongside volume 12 and The Antidepressant Era3. According to Healy, the forces that drive change in medical practice include: the drug hunters ('applied' scientists such as industrial chemists and pharmacologists, and those who screen compounds for safety and pharmacological activity); clinical researchers (who give these new drugs to people, and try to figure out what the) are doing), 'pure' biological scientists (who provide a vocabulary and structure within which this operates); regulatory bodies such as the US Food and Drug Administration (FDA) and the UK Committee on Safety of Medicines; the marketing and sales divisions ofthe pharmaceutical corporations; the epidemiologists and biostatisticians who organize and analyse clinical trials; and the great mass of clinicians who prescribe, and the patients who take, the drugs at the end of it all.
The middle years of the twentieth century saw a 'therapeutic revolution', during which the major types of psychoactive drug were discovered. This golden age of creativity and innovation has never properly been documented and has become widely misunderstood.
Largely false models of the mechanisms of clinical discovery have been used to guide policy-models that typically emphasize the role of 'pure' science and epidemiology while neglecting the contributions of industry scientists and clinicians. However, the golden age seems to be past: drug discoveries are becoming less frequent, and the solutions usually proposed may be making matters worse.
AFTER THALIDOMIDE
David Healv's historical analysis emphasizes the increasing influence of the drug regulatory bodies in the period after the thalidomide disaster in the early 1960s. The expanded regulations were designed to safeguard the public and balance the influence of pharmaceutical corporations, but some of the effects were the opposite of those intended. Although there were benefits from tighter control and riskreduction, the price has been high indeed: innovation has been throttled, the corporations have grown bigger and stronger, and the public has been denied effective new classes of pharmaceutical agents. The process of discovering, developing, testing and licensing a new pharmaceutical agent became so long drawn out that the drug industry was virtually forced to adopt a long-term, risk-minimizing strategy that thwarted primary creativity. Furthermore, only the very largest, richest and most influential pharmaceutical corporations could stay the course. Companies amalgamated, competition was reduced, and those few corporations that survived became more powerful than ever.
One effect of the regulatory changes was to reinforce prescription-only status; and, with the intention of improving the risk-benefit profile of treatment, regulators began to insist on a diagnostic indication for newb} licensed drugs. The unintended effect of this was to encourage pharmaceutical companies to sell not just drugs but also the diagnoses and disease concepts that sustain the prescription of these drugs. Eventually, via marketing, funding and information management, academic research became captive to these fundamentally commercial theories. In Healy's trilogy this tendency is extensively documented. For example, he argues that the current unitary diagnostic category of schizophrenia, and the linked quasi-aetiological hypothesis of the dopamine theory of schizophrenia, have been sustained far beyond their natural shelf-life by effective deployment as marketing slogans.
MARKETING OF DISEASE AND SCIENCE
Depression is an even clearer example. When tricyclics and monoamine oxidase inhibitors (MAQIs) were invented there was no market-niche into which the drugs could be sold. Healy uncovers the forgotten fact that, until late in the 1960s, depression was regarded as a rare, severe, illness requiring admission to hospital and best treated by electroconvulsive therapy. In his interview, the late Michael Shepherd describes how his team's epidemiological work disclosed and exhaustively characterized a large and unsuspected iceberg of moderate and mild depression, treated by general practitioners without referral to psychiatrists. It took about twenty years before this work was recognized and integrated into practice and policy.
From the late 1 950s onward, if pharmaceutical companies wanted to sell their antidepressants, doctors had to be cducated concerning the existence of a general JOURNAL OF THE ROYAL SOCIETY OF MEDICINE Vo u me 91
July 1998 category of 'depression', an illness having a plausibly biochemical aetiology (the 'monoamine theory') and responsive to drug treatment. Thousands of copies of a book by Frank Ayd on the recognition of depression were distributed free of charge by the manufacturers of amitriptyline. Such strategies were backed up by the distribution of reprinted papers, sponsorship of research, conferences, special editions of journals the whole paraphernalia of the academic infrastructure. As a result, the monoamine theory came to dominate research and marketing alike. Healy's point is a subtle and original one. 'Depression' (whatever it is, and however it is caused) was indeed underdiagnosed and undertreated, and here the role of pharmaceutical corporations seems to have been largely beneficial. Vast numbers of people have benefited from the tricyclic antidepressants, from MAOIs, and from selective serotonin reuptake inhibitors. But one of the problems is that, in order to get access to these drugs, people must submit to a diagnosis. The serious barrier of having to accept a psychiatric disease label could perhaps have been circumvented, and even more people might have benefited. In The Antidepressant Era Healy sketches out an alternative scenario. Supposing, he says, that antidepressants had been sold over the counter, directly to the public what would have been their market niche? He suggests that they might have been sold as a 'tonic' (build up your appetite, help you sleep, enable you to cope better with life) and that their indication would therefore have been symptomatic rather than diagnostic. Just as we take paracetamol for a headache, not a diagnosis, antidepressants could have been drugs to help with 'problems of living' rather than drugs for a disease category.
GREAT MINDS
One of the pleasures of The Psychopharmacologists 11 is to eavesdrop on wonderful conversations. The interview is an excellent form of discourse, under-rated and under-used. The British contributors are Linford Rees, Michael Shepherd, Gerald Curzon, Leslie Iversen, Jeff Watkins, David Wheatley, Ian Stolerman and Isaac Marks. Others include Joseph Brady, Roland Kuhn, Max Lurie, Mogens Schou, George Simpson, Per Bech and Myrna Weissman on Gerald Klerman. All the interviews are worthwhile but some stand out for example, that with the genius drug-discoverer Paul Janssen, whose triumphs include haloperidol and risperidone. His comments provide a riveting insight into the way these things are doneshall we see his like again? Len Cook was a new name to me. He was an important figure in understanding the multifarious actions of chlorpromazine, which was initially marketed for just about every indication and specialty except psychiatry. Cook emphasizes that the 1 950s discoveries of the classes of neuroleptics, tricyclics and MAOIs were made by chance, in the clinic, without prior specification of the kind of drug needed. Once the breakthrough had been made, development then consisted in creating more powerful and cleaner drugs of the same class. But this does not happen any more: now we get the development without the breakthrough. Innovation has not stopped, but has slowed. Cook blames this partly on the shifting operational style ofpharmaceutical corporations (his description of modem managers comes straight from the world of Scott Adams' Dilbert comic strip).
There is no reason to believe that our contemporary mediocrity has emerged because there are no good drugs left to be discovered. On the contrary, it seems likely that many novel classes are out there waiting to be found, and others already in use whose most useful actions have not yet been noticed. The process by which we are failing can, it seems to me, be seen in the interview with the FDA administrator Paul Leber. The pattern of his biography and opinions are unintentionally illustrative of the rigidity, narrowness and negativity which are the occupational hazard of members of regulatory organizations.
But there are grounds for optimism. The solution is attainable although not without taking some risks. Len Cook suggests that we need to create the structures for primary, exploratory clinical science: 'We should be doing far more conceptual clinical testing. For example take. . compounds which have any possibility of working for any rational reason: once they have been shown to be safe we should put them in the clinic for conceptual clinical testing using good experimental minded clinicians to see just what they do. Then we could go back to basic research and work it up further. . '. If we are to rediscover the process of discovery, clinical researchers must take a crucial role.
Healy's trilogy is a major achievement: its importance goes beyond psychiatry and psychopharmacology to embrace the whole of medicine. These books represents a quantum leap in understanding the processes that shape therapeutic innovation in clinical practice. Work of this revolutionary scope comes along infrequently perhaps once a decade. For medicine, things may never be the same again.
